Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17567263 | 0.86 | L3MBTL1 (0.46) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL21699514 | 0.86 | L3MBTL1 (0.46) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL16205770 | 0.84 | L3MBTL1 (0.43) | L3MBTL1NPSR1HTR2CSLC6A4 | |
| SCHEMBL17573255 | 0.79 | GPR88 (0.32) | L3MBTL1 | |
| SCHEMBL21699266 | 0.78 | L3MBTL1 (0.44) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL17567265 | 0.78 | L3MBTL1 (0.44) | L3MBTL1NPSR1HDAC3HDAC1HDAC2 | |
| SCHEMBL16197719 | 0.77 | CA14 (0.34) | L3MBTL1HDAC1HDAC2METAP2 | |
| SCHEMBL16197714 | 0.77 | CA14 (0.34) | L3MBTL1HDAC1HDAC2METAP2 | |
| SCHEMBL21444759 | 0.76 | L3MBTL1 (0.45) | L3MBTL1NPSR1HTR2CSLC6A4 | |
| SCHEMBL16993182 | 0.76 | L3MBTL1 (0.62) | L3MBTL1NPSR1PPARACTSSHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | L3MBTL1 3222/4885NPSR1 838/4885PPARA 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.